ReviewMethodist DeBakey cardiovascular journal
Cardiovascular Disease in Acromegaly.
Review in Methodist DeBakey cardiovascular journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Myocardial Mechanics in Acromegaly: A Meta-Analysis of Echocardiographic Studies.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024Pooled it
- Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis.Pituitary · 2018Pooled it
- Evaluation of static and dynamic pupil responses in patients with acromegaly with automatic pupillometer.BMC ophthalmology · 2026Article
- Cardiomyopathy in women with acromegaly: clinical characteristics and associated factors in a Colombian multicenter registry.Frontiers in endocrinology · 2026Article
- Cardiomyopathies of endocrine origin: A state-of-the-art review.World journal of cardiology · 2025Review
- Effects of Hormones on Left Heart Structure and Function with Echocardiography in Acromegaly.Reviews in cardiovascular medicine · 2025Article
- From Subtle Signs to Severe Sequelae-A Century of Symptomatology and Comorbidities in the Diagnosis of GH-Secreting Pituitary Neuroendocrine Tumors: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly-A Preliminary Study.Biomedicines · 2025Article
- Echocardiographic Findings in Cardiomyopathy Due to Acromegaly.Biomedicines · 2025Article
- Echocardiographic and Impedance Cardiography Analysis of Left Ventricular Diastolic Function in Acromegaly Patients.Medical science monitor : international medical journal of experimental and clinical research · 2024Observational
- Article
- Aneurysmal dilation of sinus of Valsalva in a patient with undiagnosed acromegaly.Clinical case reports · 2023Article
- 2022 Cannon lecture: an ode to signal transduction: how the growth hormone pathway revealed insight into height, malignancy, and obesity.American journal of physiology. Endocrinology and metabolism · 2023Review
- Recurrent Cardiac Myxoma: A Puzzle to be Solved.Anatolian journal of cardiology · 2023Article
- Cardiovascular Effects of Excess Growth Hormone: How Real is the Threat?Reviews in cardiovascular medicine · 2023Review
- Development and evaluation of the Acromegaly Symptom Diary.Journal of patient-reported outcomes · 2023Article
- Article
- Adherence to Acromegaly Treatment and Analysis of the Related Factors-A Real-World Study in Bulgaria.Pharmaceutics · 2023Article
- Insulin signaling in the heart is impaired by growth hormone: a direct and early event.Journal of molecular endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with acromegaly, chronic excess of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) leads to the development of acromegalic cardiomyopathy. Its main features are biventricular hypertrophy, diastolic dysfunction, and in later stages, systolic dysfunction and congestive heart failure. Surgical and/or pharmacological treatment of acromegaly and control of cardiovascular risk factors help reverse some of these pathophysiologic changes and decrease the high risk of cardiovascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.